home / stock / bct:cc / bct:cc news


BCT:CC News and Press, Briacell Therapeutics Corp. From 05/15/24

Stock Information

Company Name: Briacell Therapeutics Corp.
Stock Symbol: BCT:CC
Market: TSXC
Website: briacell.com

Menu

BCT:CC BCT:CC Quote BCT:CC Short BCT:CC News BCT:CC Articles BCT:CC Message Board
Get BCT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...

BCT:CC - Canadian Companies Moving the Markets, Morning edition
Wed, May 15, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada NFT TECHNOLOGIES INC. (NFT) fell 50.0% to $0.005 on volume of 3,644,047 shares iShares S&P/TSX 60 Index ETF (XIU) rose 0.1% to $33.85 on volume of 3,370,995 shares Manulife Financial Corporation (MFC) rose 0.6% to $35.72 on volume of 2,011,3...

BCT:CC - BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...

BCT:CC - BriaCell Announces Oral and Poster Presentations at ASCO 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD Two poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell) as authors PHILADELPHIA and VANCOUVER, British Columb...

BCT:CC - BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+(TM) and Bria-PROS+(TM) Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and natural killer (NK) cells The novel mechanisms of actio...

BCT:CC - BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior treatments in Bria-IMT™ population than in comparable studies Bri...

BCT:CC - Canadian Companies Moving the Markets, Evening edition
Wed, Mar 20, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada TC Energy Corporation (TRP) fell 1.1% to $54.04 on volume of 26,244,209 shares Calibre Mining Corp. (CXB) fell 7.2% to $1.68 on volume of 26,036,155 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 3.1% to $3.78 on volume of 12,240...

BCT:CC - Canadian Companies Moving the Markets, Evening edition
Mon, Mar 18, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 1.1% to $99.36 on volume of 15,927,514 shares Crescent Point Energy Corp. (CPG) rose 1.0% to $10.62 on volume of 11,545,321 shares Global Atomic Corporation (GLO) fell 30.7% to $2.17 on volume of 11,...

BCT:CC - Canadian Companies Moving the Markets, Morning edition
Thu, Mar 14, 2024 as of 10.00 am ET

A look at the top 10 most actives in Canada Lundin Mining Corporation (LUN) fell 0.1% to $12.7 on volume of 10,285,870 shares Canadian Natural Resources Limited (CNQ) fell 0.6% to $99.01 on volume of 6,570,639 shares TC Energy Corporation (TRP) fell 1.0% to $54.51 on volume of 4,227,716 s...

BCT:CC - Canadian Companies Moving the Markets, Evening edition
Thu, Mar 07, 2024 as of 4:00 pm ET

A look at the top 10 most actives in Canada Cenovus Energy Inc. (CVE) fell 0.0% to $24.15 on volume of 11,784,891 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 13.4% to $4.15 on volume of 11,675,241 shares Bitfarms Ltd. (BITF) fell 6.4% to $3.36 on volume of 9,646,374 sha...

BCT:CC - BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell PHILADELPHIA and VANCOUVER, British...

Previous 10 Next 10